

# Elacridar

**Catalog No: tcsc1112**



## Available Sizes

---

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg

**Size:** 200mg

**Size:** 500mg



## Specifications

---

**CAS No:**

143664-11-3

**Formula:**

$C_{34}H_{33}N_3O_5$

**Pathway:**

Membrane Transporter/Ion Channel; Membrane Transporter/Ion Channel

**Target:**

P-glycoprotein; BCRP

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 12.5 mg/mL (22.18 mM; Need ultrasonic)

**Alternative Names:**

GF120918; GW0918; GG918; GW120918

**Observed Molecular Weight:**

563.64


**Product Description**

Elacridar is a potent **P-glycoprotein (Pgp)** and **BCRP** inhibitor.

IC50 & Target: P-glycoprotein (Pgp), BCRP<sup>[1]</sup>

**In Vitro:** Elacridar inhibits P-glycoprotein (P-gp) labeling by [<sup>3</sup>H]azidopine with a IC<sub>50</sub> of 0.16 μM<sup>[2]</sup>. In Caki-1 and ACHN cells, elacridar (2.5 μM) significantly inhibits the cell growth. The P-glycoprotein activity is found to be inhibited by elacridar. The combination of elacridar and sunitinib lead to a significant reduction in ABC Sub-family B Member 2 (ABCG2) expression in 786-O cells<sup>[3]</sup>.

**In Vivo:** Oral co-administration of elacridar (100 mg/kg, p.o.) and crizotinib increases the plasma and brain concentrations and brain-to-plasma ratios of crizotinib in wild-type mice, equaling the levels in Abcb1a/1b; Abcg2<sup>-/-</sup> mice<sup>[1]</sup>. In friend leukemia virus stain B mice, the brain-to-plasma partition coefficient (K<sub>p</sub>, brain) of elacridar is 0.82, 0.43, and 4.31 after intravenous (2.5 mg/kg), intraperitoneal (100 mg/kg), and oral (100 mg/kg) treatment, respectively<sup>[4]</sup>. In Mrp4<sup>(-/-)</sup> mice, elacridar fully inhibits P-gp mediated transport of topotecan, without significant effects on Bcrp1-mediated transport<sup>[5]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!